Abstract:BackgroundLiquid biopsy has been proposed to be a promising noninvasive tool to obtain information on tumor progression. Through a clinical observation of a case series of 6 consecutive patients, we aim to determine the value of circulating tumor DNA (ctDNA) for monitoring the tumor burden during the treatment of colorectal cancer (CRC).Materials and MethodsWe used capture sequencing of 545 genes to identify somatic alternations in primary tumor tissues of the six CRC patients who underwent radical surgery and in 23 plasma samples collected at serial time points. We compared the mutation patterns and variant allele frequencies (VAFs) between the matched tissue and the plasma samples and evaluated the potential advantage of using ctDNA as a better tumor load indicator to detect disease relapse over carcinoembryonic antigen (CEA), cancer antigen (CA) 19-9 and imaging studies.ResultsWe identified low-frequency mutations with a mean VAF of 0.88% (corresponding to a mean tumor burden of 0.20ng/mL) in the preoperative plasmas of four patients with locally advanced CRC and a subset of mutations shared by their primary tumors. The tumor loads appeared a sudden decrease upon surgery or other adjuvant treatments and then generally maintained at low levels (0.092ng/mL) until disease recurred. ctDNA increased by 13-fold when disease relapsed in one patient while the CEA and CA 19-9 levels remained normal. In this patient, all six somatic mutations identified in the preoperative plasma were detected in the recrudescent plasma again, with five mutations showing allele fraction increase.ConclusionsWe described a multi-time-point profile of ctDNA of CRC patients during the course of comprehensive treatment and observed a correlation of ctDNA level with the clinically evaluated tumor progression. This demonstrated a new strategy by analyzing the heterogeneous ctDNA to evaluate and monitor the tumor burden in the treatment and follow-up of CRC patients, with potentially better potency than conventional biomarkers.

Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer

Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer

Clinical application of liquid biopsy in colorectal cancer: detection, prediction, and treatment monitoring

Liquid biopsies to monitor and direct cancer treatment in colorectal cancer

Application of Circulating Tumor DNA As a Non-Invasive Tool for Monitoring the Progression of Colorectal Cancer

Early Detection, Precision Treatment, Recurrence Monitoring: Liquid Biopsy Transforms Colorectal Cancer Therapy

Circulating Tumor Cells in Colorectal Cancer in the Era of Precision Medicine

Advances in Epigenetic Biomarker Research in Colorectal Cancer.

Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices

Circulating Tumour Cells, Circulating Tumour DNA and Circulating Tumour miRNA in Blood Assays in the Different Steps of Colorectal Cancer Management, a Review of the Evidence in 2019

Ongoing clinical trials and future research scenarios of circulating tumor DNA for the treatment of metastatic colorectal cancer

Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy

Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer

Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer

Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis

Recent Technologies towards Diagnostic and Therapeutic Applications of Circulating Nucleic Acids in Colorectal Cancers

Clinical Perspectives on Liquid Biopsy in Metastatic Colorectal Cancer

Exploring the Role of Circulating Cell-Free RNA in the Development of Colorectal Cancer

Application of Circulating Tumor DNA in Precision Diagnosis and Treatment of Colorectal Cancer

Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies

Promising clinical application of ctDNA in evaluating immunotherapy efficacy.